


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.15%
+0.13%
-10.04%
PGNY
Progyny
$25.00
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Risk Analysis

Investors losing their confidence
PGNY Price Performance
$25.57 (-2.23%)
$19.53 (+28.01%)
$23.25 (+7.53%)
$21.83 (+14.52%)
PGNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
PGNY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PGNY Street Sentiment is extremely bullish and have positive views on the near-term outlook
PGNY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
PGNY
Progyny
25.00
-1.77%
AQST
Aquestive Therapeutics
3.25
-3.27%
CFG
Citizens Financial Group
64.25
+0.30%
IMNM
Immunome
25.82
+3.82%
NOW
ServiceNow
128.56
+2.60%
What is PGNY current stock price?
What are PGNY stock strengths?
What is PGNY Risk Level?
What is PGNY market cap and volume?
What is PGNY current Stock IQ?
Should I buy PGNY stock right now?
Is PGNY a Strong Buy right now?
What does a 'Strong Buy' rating mean for PGNY?
What does a 'Strong Sell' rating mean for PGNY?
What factors influence PGNY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.15%
+0.13%
-10.04%
PGNY
Progyny
Current Price
$25.00
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Risk Analysis

Investors losing their confidence
Recently Viewed
PGNY
Progyny
25.00
-1.77%
AQST
Aquestive Therapeutics
3.25
-3.27%
CFG
Citizens Financial Group
64.25
+0.30%
IMNM
Immunome
25.82
+3.82%
NOW
ServiceNow
128.56
+2.60%

PGNY Price Performance
$25.57 (-2.23%)
$19.53 (+28.01%)
$23.25 (+7.53%)
$21.83 (+14.52%)
PGNY Analysts Opinion
PGNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
PGNY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PGNY Street Sentiment is extremely bullish and have positive views on the near-term outlook
PGNY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
Today
Upgrade
Market
Citizens
Dec 15, 2025
Upgrade
Buy
Zacks
Dec 10, 2025
Initiate
Overweight
Barclays
Nov 18, 2025
Reiterate
Hold
Canaccord Genuity
Nov 13, 2025
Upgrade
Overweight
KeyBanc
PGNY Stock IQ
PGNY Latest Analysis
Progyny Inc. (PGNY) Supported by Analysts as Earnings Visibility Improves. We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. The eleventh stock on our list is Progyny Inc. TheFly reported on January 8 that Truist upgraded PGNY to Buy from Hold and raised its price target to $34 from $28. The firm stated that while worries about ProgynyRx are increasingly [….]
Today
Citizens Upgrades Progyny (PGNY). Fintel reports that on January 20 2026 Citizens upgraded their outlook for Progyny (NasdaqGS:PGNY) from Market Perform to Market Outperform. Analyst Price Forecast Suggests 25.63% Upside
Tue Jan 20, 2026
Progyny Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Tue Jan 13, 2026
Progyny Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.
Tue Jan 13, 2026
Progyny Inc. (PGNY) Soars to 52-Week High Time to Cash Out?. Progyny (PGNY) is at a 52-week high but can investors hope for more gains in the future? We take a look at the companys fundamentals for clues.
Fri Jan 9, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PGNY Stock trends
PGNY Stock performance
PGNY Stock analysis
PGNY investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.